[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire, Amiens\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":628},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,170,0,25,[9,46,74,101,122,152,177,201,225,248,266,290,321,342,366,390,413,440,458,476,502,531,556,578,602],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644204","phase-3-comparison-of-early-pleural-irrigation-strategy-with-saline-to-the-standard-of-care-for-the-management-of-complicated-pleural-infections-100644204",false,"NCT07666464","Comparison of Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.","Randomized Controlled Trial Comparing an Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.","EPISSOC","Inclusion Criteria:\n\n* Adults (≥18 years old) capable of fully understanding the study;\n* Complicated pleural infection (macroscopically purulent fluid, positive for bacteria on Gram's staining, positive on culture for bacterial infection, loculated effusion, pH \\\u003C7.2, great abundance) leading to thoracic drainage;\n* Initial ultrasound evaluation to estimate pleural fluid abundance and detect fibrinous septation;\n* Social security affiliation\n* Written informed consent\n* Highly effective contraceptive methods for women of childbearing age include: Combined hormonal contraception (estrogen and progestogen) associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device; hormone- releasing intrauterine system; bilateral occlusion of the Fallopian tubes; vasectomized partner; sexual abstinence\n\nExclusion Criteria:\n\n* Tuberculous pleural effusions;\n* Previous treatment with intrapleural fibrinolytic agents (urokinase, streptokinase, alteplase, or DNase) or intrapleural saline lavage;\n* Previous thoracic surgery for pleural infection;\n* Contraindications to auxiliary treatments, to fibrinolysis or surgery as well as to procedures such as drainage and lavage;\n* Pregnancy or lactation;\n* Expected survival of less than 3 months;\n* Thoracic drainage since more than 24h;\n* Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision);\n* Inability to give informed written consent;\n* Participation in another clinical trial;\n* Patient being a relative of the investigator or any member of the team directly involved in the study, including assistant physicians, pharmacists, nurses, and coordinators","ALL","18 Years",{"count":21,"type":22},244,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Intrapleural enzyme therapy (IET) is regarded by recent guidelines as a \"rescue\" therapy for managing complicated pleural infections; however, it is associated with significant side effects, including pleural bleeding, pain, and fever. Pleural irrigation with saline may serve as an alternative, yet evidence supporting its effectiveness is limited to a single small- scale, single-center randomized trial. The objective of the study is to compare the risk of treatment failure at 30 days (defined as a composite outcome that includes death, the need for thoracic surgery, or additional intrapleural enzyme therapy) between an early pleural irrigation strategy and standard care for complicated pleural infections.",[28,29],"Therapy","Pleural Infections",[31,32],"therapy","pleural infections","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2026-05-13",{"date":41,"type":22},"2029-08",{"name":43,"class":44},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100493864","bioimpedance-measurement-of-abdominal-free-flaps-during-arterial-and-venous-weaning-in-breast-reconstruction-100493864","NCT05710705","Bioimpedance Measurement of Abdominal Free Flaps During Arterial and Venous Weaning in Breast Reconstruction","MONITRANS2","Inclusion Criteria:\n\n* Woman undergoing microsurgical breast reconstruction using a free abdominal flap\n* Age greater than or equal to 18 years\n\nExclusion Criteria:\n\n* Pregnant patient\n* Patient with an active implantable device such as a pacemaker or an artificial heart\n* Patient refusing to participate in the study\n* Age less than 18 years old","FEMALE",{"count":55,"type":22},10,[57],"NA","As the occurrence of thrombosis in post surgery is rare, it seemed difficult to study only this one. This is why we decided to test the bioimpedance, temperature and green, red and infrared light absorption measurements of the prototype during the weaning of the flap during surgery. Indeed, during weaning the investigators voluntarily interrupt the arterial and venous flow to transfer the flap to the breast. This weaning corresponds to a thrombosis model.\n\nThe patients will benefit from an \"improved\" postoperative monitoring. Indeed, in addition to the classical clinical monitoring, they will benefit from an additional monitoring during 5 days thanks to the realization of an ultrasound of the flap which will be carried out every 6 hours the first 24 hours then every 12 hours.\n\nThis protocol is therefore a feasibility study for the collection of data of interest.",[60,61,62],"Breast Reconstruction","Thrombosis, Venous","Bioimpedance Measurement Capacity",[64,61,65],"breast reconstruction","bioimpedance measurement capacity","2026-06-23",{"date":68,"type":37},"2026-06-24",{"date":70,"type":37},"2022-12-08",{"date":72,"type":22},"2026-12",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100333973","valvular-aortic-stenosis-prognosis-study-100333973","NCT03628313","Valvular Aortic Stenosis Prognosis Study","Valvular Aortic Stenosis Prognosis Study: Prospective and Retrospective Follow-up of a Cohort of Patients With Aortic Valve Narrowing","EPRAoV","Inclusion Criteria:\n\n* Retrospectively, all patients examined from January 1, 2000 to November 2014 will be included in the echocardiography laboratory whose objective examination is a narrowing of the aortic valve (maximum transaortic velocity ≥2.5 m \u002F s).\n* Aortic stenosis may be known in the past.\n\nExclusion Criteria:\n\n* Refusal of the patient to participate in the study.\n* Patients who have previously had aortic valve surgery before being examined in the echocardiography laboratory.\n* Patients who can not be contacted or who do not respond will not be included in the database.","100 Years",{"count":84,"type":22},3450,"OBSERVATIONAL","Aortic stenosis is the most common valvulopathy in Western countries. Cardiac EchoDoppler is the reference method for assessment of aortic stenosis and provides prognostic elements. However, it is imperfect with many inconsistencies between measures. On the other hand, the prognosis of patients with low flow and low gradient aortic retraction is discussed.\n\nThe main objective of this work is to study the prognosis of asymptomatic and symptomatic aortic retraction.",[88],"Morality",[90,91,92,93],"Echoacrdiography","EchoDoppler","Aortic valve stenosis","Prognosis",{"date":95,"type":37},"2026-06-25",{"date":97,"type":37},"2015-09-03",{"date":99,"type":22},"2026-06",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":45},"100327767","does-urinary-timp2-and-igfbp7-can-identify-high-risk-patients-of-progression-from-mild-and-moderate-to-severe-acute-kidney-injury-during-septic-shock-100327767","NCT03547414","Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock?","Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock? HEMOCHECK","HEMOCHECK","Inclusion Criteria:\n\n* Age 18 or over\n* Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines\n* AKI, characterized by a KDIGO score ≥ 1\n* Social security coverage\n\nExclusion Criteria:\n\n* AKI requiring emergency RRT (in the critical care physician's opinion).\n* Anuria\n* Stage 4-5 chronic kidney failure with a GFR below 30 ml\u002Fmin.\n* Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)\n* Obstructive AKI\n* Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis)\n* Pregnancy or breastfeeding\n* Legal guardianship or lack of social security coverage.\n* Cardiocirculatory arrest\n* Life expectancy \\\u003C48 hours.\n* Child C cirrhosis\n* Prior occurrence of AKI during the current hospital stay\n* Transplantation\n* Subject participating in another study with an exclusion period ongoing at the time of the pre-inclusion",{"count":110,"type":22},110,"Septic shock is one of the leading causes of death in patients admitted to the intensive care unit (ICU). Acute kidney injury (AKI) occurs in almost 50% of septic patients and is associated with significant mortality. Progression to the last stage (KDIGO stage 3) of AKI is an important step in the disease, as it usually requires initiation of RRT. Renal biomarkers are unable to accurately identify those patients who will progress to severe AKI (KDIGO 3). However, identification of patients at risk of progression to severe AKI could help the clinician to initiate optimal therapy including RRT. A new urine test, the Nephrocheck™ corresponding to the product of the urinary concentrations of 2 markers of renal tubule injury (TIMP2 and IGFBP7) has been validated. The Investigator have already performed two previous studies including septic shock patients (AKICHECK and BIOOCHECK). those previous datas will be reanalysed to examine whether the new urinary biomarkers TIMP2 and IGFBP7 can predict progression within 24 hours and 72 hours from mild and moderate (KDIGO 1 or 2) to severe AKI (KDIGO 3) in patients with septic shock.\n\n-All the datas required will be collected from two previous studies (AKICHECK and BIOCHECK) performed in 3 centers: Amiens medical ICU, Melun medico surgical ICU and Montpellier Medical ICU.",[113,114],"Acute Kidney Injury","Septic Shock","2026-06-15",{"date":117,"type":37},"2026-06-16",{"date":119,"type":37},"2018-05-16",{"date":99,"type":22},{"name":43,"class":44},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":139,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100540586","predictive-value-of-systolic-rise-time-of-the-plantar-arch-on-the-risk-of-major-adverse-limb-events-male-and-major-adverse-cardiovascular-events-mace-in-peripheral-artery-disease-pad-at-critical-ischaemia-stage-100540586","NCT06318767","Predictive Value of Systolic Rise Time of the Plantar Arch on the Risk of Major Adverse Limb Events (MALE) and Major Adverse Cardiovascular Events (MACE) in Peripheral Artery Disease (PAD) at Critical Ischaemia Stage","TAMIS","Inclusion Criteria:\n\n* patients at least 18 years old,\n* willing and able to provide written informed consent,\n* with documented atherosclerosis critical limb ischemia (pain rest and\u002For ulcer and gangrene manifestations)\n* with hemodynamic measures (ankle pressure less than 50mmHg and\u002For TBI less than 30mmHg and\u002For TcPO2 less than 30 mmHg),\n* followed or send to CHU Amiens Picardie, and eligible to chirurgical revascularization.\n\nExclusion Criteria:\n\n* with non atherosclerosis arteriopathy,\n* ineligible to the gold standard treatment such as the chirurgical revascularization,\n* with life expectancy less than 3 months.",{"count":130,"type":22},134,[57],"Peripheral artery disease (PAD), vascular disease of atheromatous origin, is a frequent pathology, with a steady and significant increase in prevalence over the last decades. It has various symptoms ranging from mild arterial claudication to critical limb ischemia. The critical ischaemia stage in PAD is defined by rest pain or trophic disorders and is a special situation because of the number of cardiovascular deaths at 1 year (25%), 60% at 5 years and acute ischaemic recurrence at 1 year (25%).\n\nIt is a medico-surgical pathology. A haemodynamic marker is needed to monitor patients, as it is predictive of limb progression, cardiovascular events and mortality. The Systolic Rise Time (SRT) of the plantar footpad is a recently described haemodynamic measurement of proven value in the diagnosis of PAD. The aim of this study is to show the prognostic value of the Systolic Rise Time on Major Adverse Limb Events (MALE).",[134,135,136,137,138],"Major Adverse Limb Events","Major Adverse Cardiovascular Events","Peripheral Artery Disease","Critical Limb Ischemia","Hemodynamic Measure",[140,141,142,143,144],"major adverse limb events","major adverse cardiovascular events","peripheral artery disease","critical limb ischemia","hemodynamic measure","2026-06-12",{"date":115,"type":37},{"date":148,"type":37},"2024-03-07",{"date":150,"type":22},"2026-09",{"name":43,"class":44},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":169,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":45},"100521661","etiological-study-of-persistent-velopharyngeal-insufficiency-in-children-with-operated-velopalatine-cleft-by-analysis-of-velopharyngeal-motor-skills-in-static-and-dynamic-mri-100521661","NCT06072495","Etiological Study of Persistent Velopharyngeal Insufficiency in Children With Operated Velopalatine Cleft by Analysis of Velopharyngeal Motor Skills in Static and Dynamic MRI","FENTIRM","Inclusion Criteria:\n\n* Children aged 7 to 12 years with Isolated cleft lip\n* isolated velopalatal cleft\n* Without a diagnosis of syndromic cleft or Pierre Robin sequence\n* French speaking, and French is the native language\n* Operated with a cheiloplasty (for cleft lip) or an intravelar Veloplasty (according to Sommerlad) at the Amiens University Hospital\n* Whose follow-up is done at the Amiens University Hospital\n\nExclusion Criteria:\n\n* Refusal of the parents and\u002For the patient\n* With a contraindication to MRI\n* Whose follow-up was initiated in another center and\u002For whose surgery was performed in another center\n* Whose surgical schedule has not been followed\n* Patient with severe neurological or neuropsychiatric disorders or Severe speech and language delay not related to the cleft anatomy\n* Patients treated with fixed, non-removable orthodontic treatment.","7 Years","12 Years",{"count":162,"type":22},30,[57],"Velopharyngeal insufficiency is defined as the inability of the soft palate to isolate the nasopharynx from the oropharynx. It is a frequent sequela in patients with a velopalatine cleft despite anatomical restoration of the soft palate by intravelar veloplasty at 6 months. If rehabilitation by a speech therapist is not successful, a pharyngoplasty can be discussed. In the last ten years, MRI was used in dynamic and static way, to analyzed velopharyngeal muscles, in particular Levator Veli Palatini. MRI could be used to identify the etiology of VPI in those patients, and thus allow personalized rehabilitation and surgical management. The aim of this study is to examine the differences in velopharyngeal motricity as well as velar muscles morphology, positioning, and symmetry of children with repaired cleft palate with different degrees of severity of velopharyngeal insufficiency (VPI), and children with labial cleft (noncleft palate anatomy).",[166,167,168],"Velopharyngeal Insufficiency","Real Time MRI","Cleft Palate",[166,170,171],"real time MRI","Cleft palate",{"date":115,"type":37},{"date":174,"type":37},"2024-11-06",{"date":99,"type":22},{"name":43,"class":44},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":53,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":45},"100509642","breastfeeding-failure-influence-of-smartphone-use-and-distraction-factors-100509642","NCT05916079","Breastfeeding Failure: Influence of Smartphone Use and Distraction Factors","BRIEFCALL","Inclusion Criteria:\n\n* breastfeeding mothers of Newborn breastfed infant born in the maternity ward of the Amiens-Picardie University Hospital\n\nExclusion Criteria:\n\n* Mother refusing to participate in the study; hospitalization during the neonatal period","18 Months",{"count":186,"type":22},300,"The benefits of breastfeeding no longer need to be proven. Many studies have shown its positives effects on both infants and mothers. Exclusive breastfeeding is thus recommended within the first six months of life.\n\nExcessive screen use has been shown to be harmful in many aspects of daily life. The impact upon the relation between mother and newborn infant is poorly studied.\n\nThe study aims to evaluate the impact of the use of smartphones on the success and duration of breastfeeding.",[189,190],"Breastfeeding","Smartphone",[189,192,193,194,195],"smartphone","screen","distraction","developmental care",{"date":115,"type":37},{"date":198,"type":37},"2023-02-16",{"date":99,"type":22},{"name":43,"class":44},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":210,"conditions":211,"keywords":216,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":45},"100502592","risk-factors-for-postoperative-complications-in-major-non-cardiac-surgery-post-hoc-analysis-of-the-ophique-multicentre-study-100502592","NCT05824260","Risk Factors for Postoperative Complications in Major Non-cardiac Surgery: Post-hoc Analysis of the OPHIQUE Multicentre Study","MULTIPAS","Inclusion Criteria:\n\n* Abdominal, orthopaedic or vascular surgery under general anaesthesia and with an estimated duration of surgery \\> 2 hours\n* Adult patients (age ≥ 18 years)\n* ASA score ≥ II\n* Patient with at least two of the following comorbidities: age \\> 50 years, high blood pressure (HTA), heart failure, ECG abnormality, smoking, stroke, transient ischemic attack (TIA), peripheral arterial disease (PAD), insulin-dependent or non-insulin-dependent diabetes mellitus (NIDDM), ascites, chronic renal failure (CRF)\n* Signature of the consent form\n* Affiliation to a social security scheme\n\nExclusion Criteria:\n\n* Severe untreated or unbalanced hypertension\n* Preoperative renal failure on dialysis\n* Acute heart failure\n* Acute coronary insufficiency\n* Vascular surgery with renal plasty\n* Cardiac surgery\n* Permanent laparoscopy\n* Chronic respiratory failure with home oxygen therapy\n* Acute respiratory distress syndrome with FiO2\\>60%.\n* Preoperative shock\n* Surgery under spinal anaesthesia and epidural only\n* Refusal to participate by the patient\n* Pregnant, parturient or breastfeeding women\n* Patients under guardianship or curators, under court protection or deprived of public rights\n* The patient already included in another therapeutic trial with an experimental molecule\n* Emergency surgery\n* Patients who do not want their personal data to be used in the framework of the research",{"count":209,"type":22},350,"Post-operative morbidity and mortality is related to many factors related to the patient's condition, the intra-operative period and the optimisation of intra-operative haemodynamic and respiratory parameters. Many studies have looked at the determinants and factors that increase postoperative complications. However, these have been randomised studies looking at one parameter in particular.\n\nThis analysis would be the first to investigate the determinants of postoperative complications in a large population of patients undergoing major non-cardiac surgery. This is a post-hoc analysis of patients included in the OPHIQUE study, whose main objective was to evaluate intraoperative haemodynamic management guided by a marker of tissue hypoperfusion (the respiratory quotient).",[212,213,214,215],"Goal Directed Therapy","Postoperative Morbidity","Individualised Target","Postopera Mortality",[217,218,219],"Goal directed therapy","postoperative morbi-mortality","individualised target",{"date":115,"type":37},{"date":222,"type":37},"2022-06-23",{"date":99,"type":22},{"name":43,"class":44},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":45},"100481296","evaluation-of-the-effectiveness-of-virtual-reality-self-rehabilitation-in-the-treatment-of-facial-paralysis-and-synkinesis-100481296","NCT05547152","Evaluation of the Effectiveness of Virtual Reality Self-rehabilitation in the Treatment of Facial Paralysis and Synkinesis","RéMiFaSy","Inclusion Criteria:\n\n* Patient with recent onset peripheral facial palsy (≤ 12 months).\n* Patient with peripheral facial palsy of grade ≥ III on the House \\& Brackmann score\n* Patient of legal age (≥ 18 years)\n* Patient with appropriate information and informed consent\n\nExclusion Criteria:\n\n* Patient with central facial palsy\n* Patient with peripheral facial palsy of \\> 12 months onset\n* Patient with peripheral facial palsy of grade \\\u003C III House \\& Brackmann score\n* Patient who has previously undergone palliative surgery\n* Patient undergoing a botulinum toxin injection protocol\n* Patients benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, pregnant or breast-feeding women and patients in emergency situations\n* Patients who have not provided informed consent\n* Patients with cognitive disorders that do not allow them to follow the proposed self-education protocol\n* Blind or visually impaired patients (visual acuity of the better eye after correction ≤ 4\u002F10)",{"count":233,"type":22},100,[57],"Peripheral facial palsy affects 15 to 40 people per 100,000 inhabitants and induces important functional and social repercussions. Synkinesis is a frequent after-effect of facial palsy recovery, consisting of involuntary facial spasms that disturb the gestural harmony and can go as far as a painful hypertonic spasm. More than 55% of patients recovering from facial palsy will develop transient or permanent synkinesis. These facial hypertonias have two main causes: imperfect axonal regeneration, which is all the more important as the damage is proximal, and hyperexcitability of the facial nerve nucleus due to a lack of central control. Management is therefore essential for the functional restoration of the face, especially since synkinesis do not evolve spontaneously. The main treatments are currently botulinum toxin injection, acting on the motor plate, and functional rehabilitation, consisting on local muscle relaxation and central motor control work. In recent years, therapies based on biofeedback and acting on central motor control have shown interesting results, and technological advances in virtual reality have made it possible to deepen this treatment in patients suffering from stroke, limb trauma or Parkinson's disease. In this project, the investigators evaluate the contribution of virtual reality to the management of facial palsy, and hypothesize that self-rehabilitation using this technology will improve motor control of the skin muscles and reduce complications related to their hypertonia such as synkinesis.",[237,238,239],"Peripheral Facial Palsy","Rehabilitation","Virtual Reality",[237,241,242],"rehabilitation","virtual reality",{"date":115,"type":37},{"date":245,"type":37},"2022-08-02",{"date":41,"type":22},{"name":43,"class":44},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":45},"100457864","prevalence-and-clinical-significance-of-anti-annexin-a2-antibodies-in-covid-19-infection-100457864","NCT05242159","Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection","IMMUNOCOVID","Inclusion Criteria:\n\n* 18 years and older\n* All patients hospitalized in Amiens University Hospital with COVID-19 infection\n\nExclusion Criteria:\n\n* Autoimmune diseases\n* Chronic viral infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)\n* Immunosuppressive treatment\n* Solid tumors\n* Hematological malignancies",{"count":186,"type":22},"In January 2020, researchers isolated and sequenced in China from patients with severe atypical pneumonia a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread throughout the world. SARS-CoV-2 may trigger hyperstimulation of immune system with an autoinflammatory response but also the development of an autoimmune process. These autoimmune responses may also develop through the molecular mimicry between virus and human-self components. Multiple autoantibodies have been described in COVID-19 patients.\n\nAnnexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator has been identified as a new autoantigen in antiphospholipid syndrome. ANXA2 has been identified as candidate autoantigen recognized by SARS patient sera. ANXA2 contributes also to pulmonary microvascular integrity. These data lead to identify anti-ANXA2 antibodies in COVID-19 patient sera and to know if the presence of these antibodies is associated with pulmonary injury or thrombosis in COVID-19 and represents a marker of severity.",[258],"COVID-19",[258,260],"annexin A2",{"date":115,"type":37},{"date":263,"type":37},"2021-05-28",{"date":99,"type":22},{"name":43,"class":44},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":276,"conditions":277,"keywords":281,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":45},"100454949","impact-of-comorbidities-after-radical-cystectomy-using-a-predictive-method-with-artificial-intelligence-100454949","NCT05204186","Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence","Evaluation of the Impact of COMORBIDities on Morbidity and Mortality After Radical Cystectomy for Cancer Using a Predictive Method With Artificial Intelligence","COMORBID-AI","Inclusion Criteria:\n\n* 18 years and older\n* Patient treated by radical cystectomy for bladder cancer\n\nExclusion Criteria:\n\n* Computed tomography\u002Fmagnetic resonance evidence of distant metastases.",{"count":275,"type":22},500,"Clinician and the multidisciplinary team meeting in oncologic urology (MMO) play a key-role in the decision making. An unexplained surgeon attributable variance, probably linked to the subjective \"eyeball test\" effect, was identified as a strongest factor underlying non-compliance with guide line recommendations in the management of bladder cancer. So high-quality studies that identify barriers and modulators (such as comorbidities) of provider-level adoption of guidelines and how comorbidities are associated in making therapeutic choice and their impact in bladder cancer specific survival and overall survival, are crucial. To identify patients at high risk of early death, and to improve specific guideline for treatment might be decisive.\n\nIn order to assess survival, where mortality events compete, it will be more appropriate to compute a Cumulative Incidence Function (namely CIF). The investigators will compare outcomes across patient populations to obtain information to improve clinical decision-making. Such learning will be done through the use of neural networks or by applying population-based approaches, such as Genetic Algorithms (GA), Ant Colony Systems (ACS) and Particle Swarm Optimization (PSO), using as a four-stage based approach.\n\nFirst, the investigators propose a \"pretopology space\" in order to study a dynamic phenomenon. Second, the investigators recall that the K-means approach remains one of the most used approaches for classifying a set of elements (patients \u002F persons \u002F others) into K (disjunctive) clusters. Third, the investigators propose a learning pretopology space for enhancing the clustering. Such an approach can be assimilated in spirit to one applied with high success on deep learning. Fourth and last, the investigators propose a reactive method that is able to include some new elements or remove some contained elements",[278,279,280],"Bladder Cancer","Comorbidity","Deep Learning",[278,279,282,283],"Deep learning","PSO-Particle swarm optimization",{"date":115,"type":37},{"date":286,"type":37},"2021-08-12",{"date":288,"type":22},"2028-12",{"name":43,"class":44},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":300,"conditions":301,"keywords":308,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":45},"100447298","spectroscopic-analysis-of-tongue-tumor-samples-100447298","NCT05104619","Spectroscopic Analysis of Tongue Tumor Samples.","Prospective Analysis of Tumor Tissues From the Oral Cavity by SpiderMassTM Spectroscopy","SpecTum","Inclusion Criteria:\n\n* age : 18 years and older\n* squamous cell carcinoma of the tongue\n* surgical resection as first-line treatment\n* tumor classification T1 to T4.\n\nExclusion Criteria:\n\n* metastatic disease\n* neoadjuvant therapies",{"count":299,"type":22},33,"In squamous cell carcinoma of the tongue, complete surgical resection of the tumor generally represents the primary treatment strategy. Among factors determining the disease prognostic, the surgical margins status is essential for the continued management of the patient, with or without complementary therapies. Generally, surgical margins are defined using visual and tactile elements. Unfortunately, in 15 to 30 percent of cases, they are defined as positive after histopathological examination, on average 5 to 7 days post-surgery.\n\nTechniques have recently been developed to analyze the cancerous and non-cancerous nature of tissues, using the spectral properties of tumor cells. SpiderMass™ is an instrument equipped with a probe for tissue micro-sampling and real-time molecular profile analysis. It is thus ultimately a tool for anatomopathological decision support, for diagnosis and prognosis of the disease. Used in the operating room, SpiderMass™ could also become an innovative surgical tool to precisely define cancerous areas in situ and the margins status in intraoperative conditions.\n\nBased on the principle of artificial intelligence, the SpiderMass™ machine must initially learn to recognize pathological tissues versus healthy. This project aims to accomplish this first phase of machine learning for squamous cell carcinoma of the tongue.",[302,303,304,305,306,307],"Mass Spectroscopy","Molecular Profile","Surgical Margins","Squamous Cell Carcinoma","Oral Cavity","Tongue",[309,310,311,312,313,314],"mass spectroscopy","molecular profile","surgical margins","squamous cell carcinoma","oral cavity","tongue",{"date":115,"type":37},{"date":317,"type":37},"2021-03-10",{"date":319,"type":22},"2026-10",{"name":43,"class":44},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":329,"conditions":330,"keywords":334,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":45},"100442290","efficacy-at-one-year-of-combined-injections-of-plasma-rich-in-platelets-and-hyaluronic-acid-in-knee-osteoarthritis-100442290","NCT05039463","Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis","ISPAG","Inclusion Criteria:\n\n* age : \\> 18 years old\n* Patients benefiting, in the context of knee osteoarthritis, from viscosupplementation alone or from two injections of PRP, in combination with HA, at the Amiens University Hospital.\n\nExclusion Criteria:\n\n* Patient refusal to use the data\n* Language barrier\n* Age less than 18 years old.",{"count":233,"type":22},"The French Society of Rheumatology cannot rule on the value of intra-articular injections of PRP due to the lack of hindsight and insufficient data. In fact, the injection protocols are very heterogeneous in terms of preparation method, the presence or not of leukocytes, the number of centrifugations, the volume injected, the ultrasound guidance, which makes it difficult to analyze the literature. The investigator objective is therefore to evaluate the effectiveness of combined injections of PRP and hyaluronic acid.",[331,332,333],"Knee Osteoarthritis","Hyaluronic Acid","Platelet Rich Plasma",[335,336,331],"platelet rich plasma","hyaluronic acid",{"date":115,"type":37},{"date":339,"type":37},"2021-08-16",{"date":99,"type":22},{"name":43,"class":44},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":365,"locationsCount":45},"100420349","use-of-discarded-surgery-human-tissue-specimens-for-basic-science-research-100420349","NCT04753593","Use of Discarded Surgery Human Tissue Specimens for Basic Science Research","HumTisRes","Inclusion Criteria:\n\n* Patients undergoing surgery in the Cardiac Surgery and Orthopedic Surgery departments of the CHU Amiens-Picardie\n* patients who will be beforehand informed\n* patients who will not be opposed to this study.\n\nExclusion Criteria:\n\n* HIV and hepatitis positive patients",{"count":350,"type":22},200,"Although it is now established that calcification process result from the joint and coordinated action of different cell types, many areas of shadow remain regarding the spatio-temporal implementation of these events. Highlighting these processes requires additional research to consider new approaches to clinical management of patients with such conditions. It is in this context that the investigators need to use residual human tissue fragments resulting from surgery which are not intended to be used for clinical-biological management of patients. The use of these pseudonymised human tissues will allow the investigators to conduct in vitro cell culture experiences.",[353,354],"Osteoblast","Vascular Calcification",[356,354,357,358,359,360],"osteoblast","vascular smooth muscle cell","Cardiac valve calcification","Valvular interstitial cell","bone tissue",{"date":115,"type":37},{"date":363,"type":37},"2021-01-04",{"date":99,"type":22},{"name":43,"class":44},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":374,"conditions":375,"keywords":380,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":45},"100419979","access-to-kidney-transplant-of-obese-patients-beginning-dialysis-100419979","NCT04748770","Access to Kidney Transplant of Obese Patients Beginning Dialysis","Transplantob","Inclusion Criteria:\n\n* Age over 18 years old.\n* Patients with BMI≥30 kg\u002Fm2 (for study population) and 25≤BMI≤30 kg\u002Fm2(for control population) one month after dialysis initiation.\n* Patients agree with their data collection.\n\nExclusion Criteria:\n\n* Patients with bariatric surgery history.\n* Patients needed dialysis for graft dysfunction.\n* Data loss.",{"count":233,"type":22},"Obesity is in constant increase all over the world and affects 35% of the global population according to the World Health Organisation. It is associated with other cardiovascular risk factors (particularly hypertension and diabetes) and with high morbi-mortality. It is also responsible for an increase of the risk of developing chronic kidney diseases (CKD). In fact, obese patients represent 25% of the dialysis population and Picardy is one of the most affected areas. However, their access to kidney transplant is still restricted and the reasons are not completely understood.",[376,377,378,379],"Kidney Transplant Access","Obese Patients","Dialysis","Comorbidities",[381,382,383,384],"Kidney transplant access","obese patients","dialysis","comorbidities",{"date":115,"type":37},{"date":387,"type":37},"2021-01-11",{"date":99,"type":22},{"name":43,"class":44},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":45},"100330038","medico-economic-evaluation-of-anti-vegf-treatments-in-the-treatment-of-nave-age-related-macular-degeneration-amd-a-model-adapted-to-the-french-context-100330038","NCT03577041","Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context","MEDIAL","Inclusion Criteria:\n\n* Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied),\n* Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept,\n* Patient using effective contraception if he is of childbearing age\n* Patient informed and not having made his opposition to the research,\n* Patient under social security scheme.\n\nExclusion Criteria:\n\n* Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye,\n* Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept,\n* Aphakia in the studied eye,\n* Fibrosis or retrofoveolar retinal atrophy of the eye studied,\n* Tearing of the pigment epithelium reaching my macula of the studied eye,\n* Choroidal neovascularization unrelated to AMD,\n* Diabetic retinopathy and \u002F or diabetic maculopathy proven,\n* Glycated hemoglobin greater than 12%,\n* Known hypersensitivity to pharmaceutical agents used,\n* Pregnant or lactating women,\n* Severe active intraocular inflammation, or history autoimmune or idiopathic uveitis,\n* Active or suspected ocular or periocular infection,\n* Intraocular pressure\\> 25mmHg despite two hypotonizing treatments in eye drops,\n* Patient under tutorship or curatorship or private public law.","70 Years",{"count":399,"type":22},600,"Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.",[402],"Age-related Macular Degeneration (AMD)",[404,405,406,407],"Neovascular Age-Related Macular Degeneration","Bevacizumab","Cost-Effective","Quality of life",{"date":115,"type":37},{"date":410,"type":37},"2020-01-29",{"date":99,"type":22},{"name":43,"class":44},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":439,"locationsCount":45},"100327676","characteristics-and-prognosis-of-moderate-or-severe-tricuspid-regurgitation-100327676","NCT03546231","Characteristics and Prognosis of Moderate or Severe Tricuspid Regurgitation","Clinical and Echocardiographic Characteristics and Prognosis of trIcuspid regurgiTation (EPIT): Prospective and Retrospective Follow-up of a Cohort of Patients With Moderate or Severe Tricuspid Regurgitation","EPIT","Inclusion Criteria:\n\n* Age \\>18 ans\n* inclusion criteria: moderate or severe tricuspid regurgitation\n* exclusion criteria: Refusal to participate\u002F prior surgery of the tricuspid valve",{"count":422,"type":22},400,"The tricuspid valve : its evaluation is relatively difficult in echocardiography and the management of tricuspid valve diseases remains poorly codified.",[425],"Tricuspid Valve Disease",[427,428,429,430,431,432,433,434],"Tricuspid regurgitation","tricuspid valve","surgery","outcome","prognosis","mortality","right ventricle","asymptomatic",{"date":115,"type":37},{"date":437,"type":37},"2018-03-15",{"date":99,"type":22},{"name":43,"class":44},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":45},"100302042","study-of-the-prognosis-of-infectious-endocarditis-epei-100302042","NCT03211975","Study of the Prognosis of Infectious Endocarditis (EPEI)","Study of the Prognosis of Infectious Endocarditis (EPEI): Prospective and Retrospective Follow-up of a Cohort of Patients Hospitalized for Infectious Endocarditis","EPEI","Inclusion Criteria:\n\n* all patients with certain infectious endocarditis according to Duke's criteria, confirmed by the presence of evocative images on the transthoracic and \u002F or transesophageal ultrasound or by the data collected on the surgical specimens.\n\nExclusion Criteria:\n\n* Patients with an infection not meeting the Duke IE criteria.",{"count":449,"type":22},645,"Infectious endocarditis (IE) is the localization and proliferation of blood-borne germs in the endocardium. It remains a complicated disease to manage due to its low incidence, diagnostic difficulties, the change in epidemiology in recent decades and high mortality rates. The annual incidence is estimated at 3-10 cases per 100,000 people.\n\nThe epidemiology of AR has changed significantly in recent years due to new risk factors. Indeed, the frequency of rheumatic heart disease, which was the first predisposing factor, decreased markedly in the industrialized countries, replaced by new predisposing factors: the presence of valvular prostheses or intracardiac materials (the risk of AR is multiplied by 50 Compared with the general population), hemodialysis, nosocomial infections, immunosuppression, increased use of injectable treatments and, above all, an aging population with an increase in degenerative diseases such as aortic stenosis and l Mitral insufficiency.\n\nThe diagnosis of IA is based on DUKE criteria. But the clinical presentation is sometimes atypical especially in case of infection on prosthesis where the diagnosis is based mainly on the results of the blood cultures and the ultrasound data.\n\nThe lesions visualized in ultrasound are: vegetations, abscesses, pseudo-aneurysms and fistulas constituting the degenerated abscess evolution, the perforation of the cusps of the native valve or the bioprosthesis giving rise to a jet of Eccentric regurgitation.\n\nThe evolution of endocarditis and its prognosis vary according to many factors: the type of germ responsible, the precocity of the diagnosis, the existence of a complication, the site of occurrence. These complications of endocarditis are frequent, sometimes revealing. EI is complicated by heart failure, atrioventricular conduction disorders, peri-vascular abscesses, embolic, neurological, renal and septic complications. Despite improvements in diagnosis and therapeutic methods, diagnosis is sometimes difficult, management remains very complicated and morbidity and mortality remain high. Studies are still needed to study the prognosis and to determine the predictive factors for hospital mortality and long-term mortality.",[452],"Endocarditis Infective",{"date":115,"type":37},{"date":455,"type":37},"2017-02-27",{"date":99,"type":22},{"name":43,"class":44},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":45},"100296499","follow-up-of-a-cohort-of-patients-with-aortic-valve-bicuspidia-100296499","NCT03139786","Follow-up of a Cohort of Patients With Aortic Valve Bicuspidia","Prospective Follow-up of a Cohort of Patients With Aortic Valve Bicuspidia: Multicentre Study","Inclusion Criteria:\n\n* All patients examined in the echocardiography laboratory whose objective examination was a bicuspid valve of the aortic valve\n* Bicuspidia may be formerly known\n\nExclusion Criteria:\n\n* Refusal to participate\n* Patients who had already undergone bicuspid surgery or ascending aorta before being examined at the echocardiography laboratory",{"count":466,"type":22},232,"The aortic valve bicuspidia (BVA) is a congenital condition corresponding to the presence of 2 sigmoids instead of 3. This is the most common cardiac congenital anomaly affecting 0.5 to 2% of the population The general rule. BVA may be associated with structural damage to the ascending aorta, which exposes BVA patients to a risk of developing ascending aortic aneurysm and acute aortic accidents. Recent data from the literature have revealed that the natural history of BVA is marked by a possible development towards significant valvulopathy and \u002F or an ascending aortic aneurysm often requiring surgical treatment. However, the natural history of bicuspid disease remains poorly understood and the prognostic factors for progression to severe valvulopathy and \u002F or aneurysmal dilatation of the ascending aorta remain to be determined.",[469],"Aortic Valve, Bicuspid",{"date":115,"type":37},{"date":472,"type":37},"2010-09-16",{"date":474,"type":22},"2035-04",{"name":43,"class":44},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":483,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":493,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":45},"100642181","validation-in-a-pediatric-population-of-a-french-translation-of-the-mepsmepi-score-100642181","NCT07624474","Validation, in a Pediatric Population, of a French Translation of the MEPS\u002FMEPI Score","MEPS-Fr","Inclusion Criteria:\n\n* Pre-test volunteer group:\n* Patients aged 4 to 17 years followed in the department without an elbow injury\n* Follow-up schedule compatible with the study protocol\n* No objection from a parent or legal guardian, with the child's consent if age permits\n* Test volunteer group:\n* Patients aged 4 to 17 years followed in the department with a diagnosis of an elbow injury\n* Follow-up schedule compatible with the study protocol\n* No objection from a parent or legal guardian, with the child's consent\n\nExclusion Criteria:\n\n* Pre-test volunteer group:\n* Language barrier, lack of understanding of French\n* Refusal to participate\n* Confounding factor impairing function\n* Opposition of parent or legal guardian and\u002For refusal of child if age permits\n* Test volunteer group:\n* Language barrier, lack of understanding of French\n* Refusal to participate\n* Confounding factor impairing function\n* Opposition of parent or legal guardian and\u002For refusal of child if age permits","4 Years","17 Years",{"count":5,"type":22},[57],"The MEPI (Modified Elbow Performance Index) or MEPS (Modified Elbow Performance Score) is a multidimensional assessment scale for elbow pain and function. This score is widely used in scientific literature, particularly for post-traumatic and post-operative evaluation, including in many French-language studies. However, no French translation of this score has undergone quality criteria verification and validation in a pediatric population.",[489,490,491,492],"MEPI","MEPS","PREE","DASH Elbow",[489,490,491,494],"DASH elbow","2026-06-10",{"date":145,"type":37},{"date":498,"type":37},"2026-04-13",{"date":500,"type":22},"2028-07",{"name":43,"class":44},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":509,"sex":53,"minAge":19,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":519,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":45},"100489055","immune-profile-analysis-and-biomarker-identification-in-women-with-repeated-implantation-failure-or-unexplained-recurrent-spontaneous-miscarriage-100489055","NCT05648136","Immune Profile Analysis and Biomarker Identification in Women With Repeated Implantation Failure or Unexplained Recurrent Spontaneous Miscarriage","ERIM","Inclusion Criteria:\n\n* For patients :\n* Women aged 18 to 39 years\n* women with a history of RIF or unexplained RM\n* women with a negative diagnostic work-up (including pelvic ultrasound and hysteroscopy, parental karyotype, thyroid function test, and anti-thyroid and anti-phospholipid antibodies)\n* women with a basal FSH level \\\u003C10IU\u002Fl and AMH level \\>1.5ng\u002Fml\n* women with a regular menstrual cycle of 30+\u002F-5 days\n* women receiving a new cycle of in vitro fertilization (IVF) +\u002F- intracytoplasmic sperm injection (ICSI) for patients in the RIF group or a first cycle of IVF +\u002F-ICSI for patients in the RM group\n* women received written and oral information and signed an informed consent\n\nFor control groups:\n\n* Controls recruited in the Obstetrics and Gynecology Department with at least one live birth after a spontaneous pregnancy (with a time to conception of less than 12 months for each pregnancy) Voluntary oocyte donors recruited within the CECOS de Picardie (having presented at least one live birth with a delay necessary to conceive of less than 12 months)\n* Controls recruited in the Reproductive Medicine and Biology Department having presented at least one live birth (spontaneous with a delay to conceive of less than 12 months for each pregnancy or after one or two MPA procedures) and benefiting from an IVF+\u002F-ICSI procedure for secondary infertility\n* Controls recruited in the department of Medicine and Reproductive Biology with a normal infertility assessment and benefiting from an IVF procedure with ICSI on male indication.\n\nExclusion Criteria:\n\n* Ongoing pelvic and\u002For systemic infection\n* Chronic infectious endometritis\n* Active neoplasia\n* Autoimmune and autoinflammatory disease\n* Celiac disease\n* Thrombophilia (including positive anti-phospholipid antibodies)\n* Endocrine pathology (including dysthyroidism and diabetes)\n* Endometriosis\n* Polycystic ovary syndrome and ovulatory disorders\n* Premature ovarian failure\n* IVF by oocyte donation\n* Tubal obstructions or lesions, uterine and cervical anomalies\n* Partners with extreme oligoastheno-spermia and\u002For sperm DNA fragmentation \\>30\n* Sperm donations\n* Patients unable to give informed consent",true,"39 Years",{"count":512,"type":22},150,[57],"Implantation is a determining step in human reproduction which requires the transition from a pro-inflammatory state to an anti-inflammatory state allowing the implantation of a competent embryo within a receptive endometrium, and then the maternal immunotolerance towards the alloantigenic fetus. Repeat implantation failures (RIFs), that refers to the fail to achieve a clinical pregnancy after the transfer of at least 3-4 good quality embryos or two blastocysts, and unexplained recurrent spontaneous miscarriage (RM) (≥2-3) could be related in some patients to immune imbalances characterized by an excessive and prolonged inflammatory response and\u002For a defect of anti-inflammatory regulation. In this context, several therapies have been evaluated in patients with RIFs or RMs in order to restore the immune balance, with heterogeneous results. No serum biomarker assay has been routinely approved to identify patients with immune imbalances that may explain repeated pregnancy failures and to predict the success of the subsequent IVF\u002FICSI cycle. The immunological analysis on peripheral blood will be based on the determination of the proportions of immune subpopulations (e.g. CD4+ et CD8+, TH1, TH2, TH17, Treg, ILC 1, ILC2, and ILC3) on the one hand and the circulating level of plasma cytokines on the other hand.",[516,517,518],"Repeated Embryo Implantation Failure","Recurrent Miscarriage","Immune System",[520,521,522,523],"repeated embryo implantation failure","recurrent spontaneous miscarriage","immunological analysis","immune system",{"date":525,"type":37},"2026-06-11",{"date":527,"type":37},"2024-08-26",{"date":529,"type":22},"2026-08",{"name":43,"class":44},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":541,"conditions":542,"keywords":546,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":45},"100643397","early-18f-fdg-pet-dynamic-analysis-in-brain-metastases-after-radiotherapy-100643397","NCT07632092","Early [18F]-FDG PET Dynamic Analysis in Brain Metastases After Radiotherapy.","Interest of Early Dynamic Analysis of [18F]-FDG PET Images in the Differential Diagnosis Between Recurrence and Radionecrosis in Brain Metastases.","DYNFDGTEP","Inclusion Criteria:\n\n* Patient referred for cerebral \\[18F\\]-FDG PET examination prescribed as part of his usual medical care for brain metastasis.\n* Age ≥ 18 years old\n* Affiliation to a social security program\n* Ability of the subject to understand and express his consent\n\nExclusion Criteria:\n\n* Age under 18 years old\n* Person under guardianship or curatorship\n* Pregnant or breastfeeding woman\n* Primary brain tumors\n* Brain metastases from renal, thyroid or other cancers known to have low avidity for \\[18F\\]-FDG",{"count":540,"type":22},50,"Various treatment options are available for brain metastases, depending on factors such as lesion site or number lesions. Radiotherapy is a commonly used treatment. Following stereotactic radiotherapy for brain metastases, a potential complication, namely brain radionecrosis, can occur subsequently. It is essential to differentiate between this radionecrosis and lesion recurrence in order to determine the appropriate treatment approach. Contrast-enhanced magnetic resonance imaging (MRI) is the most widely used technique for monitoring brain metastases. Therefore, patients undergo routine MRI at 3 months and during subsequent follow-ups, but if the lesion evolve and if distinguishing between recurrence and radionecrosis is challenging, an \\[18F\\]-FDG PET scan is then prescribed by oncologists or radiotherapists during follow-up consultations. As part of the standard patient management protocol, a 10-minute image acquisition begins after a 45-60 minutes wait following the radiotracer injection. A second image acquisition is then conducted 3-4 hours later. For both acquisitions, a low-dose X-ray scanner is synchronously coupled to allow attenuation correction of the PET images.\n\nPatient for whom a \\[18F\\]-FDG PET cerebral examination has been prescribed as part of the usual management of brain metastases will be eligible to the protocol. If the patient agrees to participate, an early imaging session is initiated immediately upon radiotracer injection, lasting 15 minutes in addition to the standard acquisition protocol.",[543,544,545],"Short Time Examination","Brain Metastases","Radiation Necrosis",[547,543,544,545],"18F]-FDG PET","2026-06-02",{"date":550,"type":37},"2026-06-08",{"date":552,"type":37},"2026-05-18",{"date":554,"type":22},"2028-11-18",{"name":43,"class":44},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":45},"100595791","phase-3-hydrocortisone-plus-fludrocortisone-in-high-risk-patients-undergoing-for-cardiac-surgery-100595791","NCT07037043","Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery","VASOCORT","Inclusion Criteria:\n\n* Age \\> 18 years.\n* Patient at intermediate\u002Fhigh risk (EuroSCORE II \\> 4%).\n* Patient admitted for scheduled cardiac surgery:\n\n  * Coronary artery bypass grafting (CABG).\n  * Aortic valve replacement.\n  * Mitral valve repair or replacement.\n  * Surgery of the aortic root (aortic tube, Bentall procedure, Tirone David procedure, or other).\n  * Combined surgery.\n* Patient undergoing cardiopulmonary bypass (CPB).\n* Informed consent signed by the patient.\n\nExclusion Criteria:\n\n* Endocarditis\n* Off-pump heart surgery\n* Heart transplantation or long-term ventricular assist device (VAD)\n* Emergency surgery: aortic dissection, emergency coronary artery bypass grafting (CABG)\n* Failure to wean from CPB requiring short-term mechanical support (intra-aortic balloon pump, ECMO)\n* Hypothermic surgery\n* History of cardiac surgery\n* Patient on long-term corticosteroid therapy\n* Autoimmune disease or chronic inflammatory condition\n* End-stage renal disease on long-term dialysis\n* Contraindications to the administration of hydrocortisone and\u002For fludrocortisone according to the summary of product characteristics (SmPC)\n* Pregnant or breastfeeding woman\n* Patient under legal protection (guardianship, curators, or judicial safeguard).",{"count":564,"type":22},196,[25],"Cardiac surgery is a high-risk surgery and is associated with a rate of postoperative adverse outcomes. Like many others major surgery, cardiac surgery procedures induce a proinflammatory phase usually counterbalanced with an immunosuppressive phase so the immune response remained balanced.\n\nIn some cases, the immune response might be dysregulated with a more pronounced pro inflammatory state that compromises organ perfusion and with the occurrence of organ failure. From a mechanistic approach, the relationship between organ failure is complex and multifactorial with a high level of proinflammatory cytokines, a decrease in microcirculation, an endothelial dysfunction and an activation of coagulation and over. The clinical expression is an increase in vasopressor exposure and dose, an increase in mortality and in adverse outcomes with a predominance of acute kidney injury.\n\nVarious therapies have been assessed to manage cardiac surgery related sepsis including glucocorticoid therapy. Briefly, two major randomized trials assessed glucocorticoid therapy solely in scheduled cardiac surgery with cardiopulmonary bypass. No clinical benefit was demonstrated in term of reduction in postoperative mortality or adverse outcomes. Since, data support that the selection of patients at risk is crucial to demonstrate such a strategy. Indeed, data support that surprisingly some patients will have a very light immune response reflected by a low pro inflammatory cytokine.\n\nThe hypothesis is that the combination glucocorticoid and fludrocortisone could decrease adverse outcomes in selected patients.",[568],"Inflammation in Cardiac Surgery",[570],"Control of inflammation in cardiac surgery",{"date":572,"type":37},"2026-06-03",{"date":574,"type":37},"2025-04-30",{"date":576,"type":22},"2028-06",{"name":43,"class":44},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":588,"conditions":589,"keywords":592,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":45},"100498716","evaluation-of-social-cognition-in-patient-with-type-1-or-type-2-narcolepsy-versus-patients-with-idiopathic-hypersomnia-100498716","NCT05773872","Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia","COGNAR","Inclusion Criteria:\n\n* adult patients (\\>\u002F= 18years old)\n* diagnosis of type 1 or type 2 narcolepsy or idiopathic hypersomnia\n* non opposition\n\nExclusion Criteria:\n\n* comorbid psychiatric or neurologic disease\n* patient under 18 years old\n* patient under guardianship, curators or deprived of liberty, refusal of the patient",{"count":586,"type":22},75,[57],"Narcolepsy is a chronic disabling neurologic disorder mainly characterised by excessive daytime sleepiness. Type 1 narcolepsy is associated with a deficit of hypocretin in the cerebrospinal fluid responsible for the cataplexy symptom while type 2 shows a normal hypocretin level and no cataplexy. While the development of narcolepsy is independent of parental social level, narcolepsy has a significant influence on educational level, grading, social outcome, and welfare consequences. Several studies assessed global cognition efficiency, mood, and attention in narcoleptic patients but only a few specifically measured social cognition and mostly without a control group.\n\nIn a population of narcoleptics children, a severe impairment in social cognition is described for 20% of the group, contrary to 2 % for the control group. The literature also depicts some impairments in decision making, somatic and cognitive emotions responses but the emotion recognition seems to be preserved.\n\nA better understanding of the social and cognitive aspects of narcolepsy could lead to a better treatment of the disease in its entirety, including if relevant specific cognitive behavioural therapy.\n\nThe protocol consists in a psychometric evaluation including several questionnaires in order to assess social cognition. It will be proposed to patients with type 1 or type 2 narcolepsy and patients with idiopathic hypersomnia.",[590,591],"Narcolepsy","Social Cognition",[590,593],"social cognition","2026-05-28",{"date":596,"type":37},"2026-06-01",{"date":598,"type":37},"2022-11-18",{"date":600,"type":22},"2027-05",{"name":43,"class":44},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":611,"conditions":612,"keywords":615,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":45},"100520268","predictive-value-of-right-atrial-strain-in-postoperative-atrial-fibrillation-in-patients-undergoing-cardiac-surgery-100520268","NCT06054360","Predictive Value of Right Atrial Strain in Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","ODFAPO","Inclusion Criteria:\n\n* Adult patient (\\>18 years old)\n* The patient was hospitalized at the Amiens University Hospital for scheduled aortocoronary bypass grafting under cardiopulmonary bypass.\n* Echocardiographic image quality enabling the measurement of RAS parameters\n* Patient affiliation to a social security scheme\n* Patient\u002Fproxy information and collection of their non-opposition.\n\nExclusion Criteria:\n\n* Patients participating in an interventional study may modify the incidence of POAF.\n* History of atrial fibrillation or flutter.\n* Valvular and ascending aorta cardiac surgery\n* Urgent cardiac surgery.\n* Presence of tricuspid insufficiency greater than grade 2.\n* Left ventricular ejection fraction lower than 50%.\n* Patient receiving circulatory mechanical assistance before surgery.\n* Dependency on ventricular and atrial pacing by an internal or external cardiac pacemaker during the echocardiographic examination.",{"count":610,"type":22},334,"The incidence of postoperative atrial fibrillation (POAF) after cardiac surgery is around 30%. POAF increases the risk of developing permanent atrial fibrillation and raises the risk of cardiac decompensation, stroke, acute myocardial infarction, and death. While the role of the left atrium (LAF) in the pathophysiology of POAF is now well-established, the part of the right atrium (RA) remains poorly understood. Recent studies suggest a correlation between RA function and POAF.\n\nRA function can be assessed by transthoracic echocardiography (TTE) with dedicated software for measuring the RA strain (RAS). RA function is thus divided into three phases: reservoir (RASr), conduit, and contraction. Numerous studies have demonstrated that a significant alteration in RAS predicts POAF in various clinical contexts. Therefore, it is essential to investigate whether alterations in RA function assessed by 2D-STE (RAS) are associated with an increased occurrence of FAPO after cardiac surgery.\n\nIt is essential to investigate whether alterations in RA function assessed by 2D-STE (RAS) are associated with an increased occurrence of FAPO after cardiac surgery.",[613,614],"Postoperative Atrial Fibrillation","Strains",[616,617,618,619,620],"coronary bypass grafting","postoperative atrial fibrillation","strain","left atrial","right atrial","2026-05-27",{"date":594,"type":37},{"date":624,"type":37},"2023-10-09",{"date":626,"type":22},"2026-10-09",{"name":43,"class":44},""]